Lutathera<sup>®</sup> Orphans: State of the Art and Future Application of Radioligand Therapy with <sup>177</sup>Lu-DOTATATE

Lutathera<sup>®</sup> Orphans: State of the Art and Future Application of Radioligand Therapy with <sup>177</sup>Lu-DOTATATE

Lutathera<sup>®</sup> is the first EMA- and FDA-approved radiopharmaceutical for radioligand therapy (RLT). Currently, on the legacy of the NETTER1 trial, only adult patients with progressive unresectable somatostatin receptor (SSTR) positive gastroenteropancreatic (GEP) neuroendocrine n...

Full description

Bibliographic Details
Main Authors: Luca Urso, Alberto Nieri, Licia Uccelli, Angelo Castello, Paolo Artioli, Corrado Cittanti, Maria Cristina Marzola, Luigia Florimonte, Massimo Castellani, Sergio Bissoli, Francesca Porto, Alessandra Boschi, Laura Evangelista, Mirco Bartolomei
Format: Article
Language:English
Published: MDPI AG 2023-03-01
Series:Pharmaceutics
Subjects:
Lutathera<sup>®</sup>
<sup>177</sup>Lu-DOTATATE
thera(g)nostics
radioligand therapy (RLT)
peptide receptor radionuclide therapy (PRRT)
somatostatin receptor (SSTR)
Online Access:https://www.mdpi.com/1999-4923/15/4/1110

Internet

https://www.mdpi.com/1999-4923/15/4/1110

Similar Items